RxDoctor Payments Data

Simhean Lee, MD

Allergy · Las Vegas, NVNPI 1912921818

Payments from drug & device makers

$7,653in general payments, 2019–2025

Across 51 payments — averaging $150.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$4K
  • AstraZeneca$757
  • Regeneron Healthcare Solutions, Inc.$441
  • Amgen$435
  • Intuitive Surgical$344
  • AbbVie$267
  • plus $964 from 11 others

What the payments were for

  • Speaking & faculty fees$3,60047%
  • Food & beverage$3,86551%
  • Education$1872%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy providers in Nevadato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$266,340
Medicare patients
113
Services billed
7,952

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab40$174,796
XolairOmalizumab17$54,689
Trelegy ElliptaFluticasone/Umeclidin/Vilanter61$40,846
Azelastine Hcl315$9,962
Advair HfaFluticasone Propion/Salmeterol25$9,601
Spiriva RespimatTiotropium Bromide11$5,920
Fluticasone Propionate254$3,116
Arnuity ElliptaFluticasone Furoate13$3,080
Fluticasone-SalmeterolFluticasone Propion/Salmeterol28$2,770
Ipratropium Bromide167$2,623
Hydroxyzine Hcl70$2,061
Albuterol Sulfate HfaAlbuterol Sulfate66$1,510
Ventolin HfaAlbuterol Sulfate14$745
Montelukast Sodium102$613
Doxepin Hcl19$451

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Arnuity Ellipta$4,444$43,92674 claims
Boehringer IngelheimSpiriva Respimat$182$5,92011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Nevadaon file to place this against a meaningful peer group, so we don't.

Other allergy in Las Vegas

Where these figures come from

Is this you, or does something look wrong? →